Award recordCONTRACT

EXELAN PHARMACEUTICALS INC

PIID 36C25226P0108· VHA· 252-NETWORK CONTRACT OFFICE 12 (36C252)· 6505 · DRUGS AND BIOLOGICALS· FY2026· $2,500,000 net obligations· UEI FYZXNHSQTMG8· FL

Description

GENERIC LENALIDOMIDE - P00001-DE-OBLIGATION OF EXCESS FUNDS.

Base award description: GENERIC LENALIDOMIDE

First action · last action
2025-12-11 · 2026-07-22
Transactions
2
First transaction's obligation
$3,000,000
Base + all options value (sum of deltas)
$2,500,000
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$3,000,000$0Base award · 2025-12-11 · this action $3,000,000 · running total $3,000,000Modification P00001 · 2026-07-22 · this action -$500,000 · running total $2,500,000
  • Base2025-12-11+$3,000,000= $3,000,000
  • Mod P000012026-07-22-$500,000= $2,500,000
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2025-12-11+$3,000,000$3,000,000GENERIC LENALIDOMIDE
Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2026-07-22−$500,000$2,500,000GENERIC LENALIDOMIDE - P00001-DE-OBLIGATION OF EXCESS FUNDS.

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI FYZXNHSQTMG8)

AwardOffice · PSC / listingNet obligationsFY
36C24226N0564242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS$5,337,256FY2026
36C25926F0197NETWORK CONTRACT OFFICE 19 (36C259) · 6505 · DRUGS AND BIOLOGICALS$1,844,059FY2026
36C26026F0261260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$918,831FY2026
36E79726D0021NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36C26026F0169260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$712,808FY2026
36C24426N0400244-NETWORK CONTRACT OFFICE 4 (36C244) · 6505 · DRUGS AND BIOLOGICALS$1,487,248FY2026

Other recipients under 6505 from 252-NETWORK CONTRACT OFFICE 12 (36C252) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C25226N0549AMERICAN NATIONAL RED CROSS, THE252-NETWORK CONTRACT OFFICE 12 (36C252)$170FY2026
36C25226N0550AMERICAN NATIONAL RED CROSS, THE252-NETWORK CONTRACT OFFICE 12 (36C252)$2,500FY2026
36C25226N0551AMERICAN NATIONAL RED CROSS, THE252-NETWORK CONTRACT OFFICE 12 (36C252)$2,100FY2026
36C25226N0548AMERICAN NATIONAL RED CROSS, THE252-NETWORK CONTRACT OFFICE 12 (36C252)$10,000FY2026
36C25226N0450BOSTON SCIENTIFIC CORP252-NETWORK CONTRACT OFFICE 12 (36C252)$607,804FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25226P0108_3600_-NONE-_-NONE- · retrieved 2026-09-26.